## Untargeted metabolomic analysis combined with multivariate statistics reveal distinct metabolic changes in GPR40 agonists-treated animals related to bile acid metabolism

## Hannes Doerfler<sup>1\*</sup>, Dana-Adriana Botesteanu<sup>2</sup>, Stefan Blech<sup>1</sup> and Ralf Laux<sup>1</sup>

<sup>1</sup>Department of Drug Metabolism & Pharmacokinetics, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach (Riß), Germany

<sup>2</sup>Department of Drug Discovery Sciences, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria

## \*Address for correspondence:

Dr. Hannes Doerfler, Boehringer Ingelheim Pharma GmbH & Co. KG, Drug Metabolism & Pharmacokinetics, Biberach (Riß), Germany. E-Mail: hannes.doerfler@gmx.at

N Samples control vs. treatment, 2,3,4x n replicates										N	к Х N							Km/z Mass/RT/DT-aligned 100s to 1000s difference in intensity							
A	В	С	D	E	F	G	н	1	J	K	L	м	N	0	P	Q	R	S	т	U	V	W	х	Y	Z
Primary	/Id Item desc	Gender	Group ID	Species	Dose	Study ID	Subject II	D Sample ty	346.05619	968.474559	68.14464	968.81241	783.36571	810.40071	832.38194	754.43491	427.11799	309.10797	274.00267	357.08220	411.12273	194.045584	11.08139	253.118914	30.1095
n/z									346.0562	968.4746	968.1446	968.8124	783.3657	810.4007	832.3819	754.4349	427.118	309.108	274.0027	357.0822	411.1227	194.0456	411.0814	253.1189	430.109
Retenti	onTime								6.774	7.101	7.109	7.115	7.176	7.362	7.374	7.381	7.543	7.653	7.803	7.881	8.007	8.377	8.382	8.41	8.44
DriftTin	ne								2.97	4.27	4.27	4.23	6.5	6.79	7.11	4.45	3.61	2.84	2.52	3.05	3.61	2.03	4.34	2.42	4.0
Comme	nt																								
patch1	sample 1	02 1:1 A (5	0+50uL_3	5uL inj) neg				Reference	0	0	0	0	0	0	0	0	0	0	0	236.33	720.72	0	0	0	
batch1	sample 1	03 1:1 A (5	0+50uL_ 3	5uL inj) neg				Reference	0	408.56	264.36	318.43	0	804.53	0	232.4	0	0	418.06	616.3	0	204.88	0	263.15	
batch1	sample 1	04 1:1 A (5	0+50uL_3	5uL inj) neg				Reference	0	0	0	0	0	0	0	0	0	0	0	276.22	0	0	0	0	
batch1	sample 1	05 1:1 A (5	0+50uL_3	SuL inj) neg				Reference	0	0	0	0	0	0	0	0	0	0	0	355.49	534.99	0	0	0	
patch1	sample 1	05 1:1 A (5	0+500L_3	Sul inj) neg Eul ini) neg				Reference	0	0	0	0	0		0	0	266.62	0	0	397.94	770.03	0	0	0	
patch1	sample 1	02 1-1 A (5	0+50uL_3	Sul inj) neg				Reference	0	0	0	0	0	0	0	0	200.03	0	0	240.37	052 52	0	0	0	
atch1	sample 1	00 1-1 A (5	0+5001_3	Sul inj) neg				Reference	0	0	0	0	0	0	0	0	275.00	0	0	460.14	532.33	0	0	0	
atch1	sample 1	10 1-1 A (5	0+50ut_ 3	Sul inj) neg Sul ini) nog				Reference	212 74	0	0	0	0	0	0	0	0	0	0	405.14	909 42	0	0	0	456.2
atch2	sample 5	01 1-1 4 (5	0+50ul_3	Sul ini) neg				Unknown	0	0	0	0	0	0	0	0	0	0	0	294.89	030.45	0	0	282.23	283
atch2	sample 5	04 1·1 A (5	0+50ul 3	Sul ini) neg				Unknown	0	0	0	0	0	238.31	0	0	0	0	0	501.53	465.04	0	0	412.36	200.
atch2	sample 5	06 1:1 A (5	0+50uL 3	SuL ini) neg				Unknown	0	0	0	0	0	0	0	0	0	234.43	0	734.64	660.24	0	0	511.27	
atch2	sample 5	07 1:1 A (5	0+50uL 3	SuL ini) neg				Unknown	0	0	0	0	0	335.79	0	0	0	0	0	209.75	474.96	0	0	319.55	280.1
atch2	sample 5	08 1:1 A (5	0+50uL 3	5uL ini) neg				Unknown	0	0	0	0	0	0	0	0	0	0	0	210.4	0	0	0	314.43	241.7

**Supplementary Figure 1. A typical data sheet as example of a megavariate problem.** The variables K (m/z features, in columns) are in excess compared to the observations, N (rows). In our case, the variables are singly charged precursor ions aligned by retention time (RT) and drift time (DT); one observation corresponds to one LC-MS run of a biological replicate.

221.88 342.32 267.72



Supplementary Figure 2. MS/MS data of CDCA-24G: reference vs. signal in rat and dog



Supplementary Figure 3. MS/MS data of 7-HOCA: reference vs. signal in rat and dog



Supplementary Figure 4. MS/MS data of DCA, GCA, GDCA and HDCA (see Table 1)







Supplementary Figure 5. Structures of BI-1 and BI-2



Supplementary Figure 6. ALT (panel A), AST (panel B) and ASP (panel C) enzyme levels in the control (N = 9) and treated (N = 6) mouse samples